Impact of β 3 ‐adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder
BJU International · 2025
DOI: 10.1111/bju.16771 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Jee Soo Park und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Adrenergic beta-3 Receptor Agonists, Urinary Bladder, Overactive, Acetanilides, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Objectives
To determine the effect of β 3 ‐adrenergic receptor (AR) agonist on the risk of kidney cancer in patients with overactive bladder (OAB). Patients and methods A nationwide population cohort study was conducted using data from the Korean National Health Insurance System database between January 2016 and December 2023. Validation analyses were performed using clinical data from patients with OAB treated with mirabegron or anticholinergics at a tertiary referral hospital between January 2014 and December 2023. The main exposure was intake of β 3 ‐AR agonist or anticholinergics, and the main outcome was incidence of kidney cancer.
Results
Of the 1 419 148 patients (61.6% male; median [interquartile range] age, 64 [53–73] years), 3229 developed kidney cancer after OAB treatment. The incidence rate of kidney cancer was 0.7 per 1000 person‐years in the mirabegron group and 0.5 per 1000 person‐years in the anticholinergic group. Among the validation data of 3108 patients (49.3% male; mean [standard deviation] age, 63.9 [13.3] years), 45 (1.4%) developed kidney cancer after OAB treatment. The mirabegron group had a higher incidence of kidney cancer (1.8%) than the anticholinergic group (0.7%) ( P = 0.025).
Conclusions
Use of β 3 ‐AR agonists was associated with an increased risk of kidney cancer compared with anticholinergics. While these findings suggest a potential association between mirabegron use and kidney cancer, further studies are needed to confirm causality. Clinicians should exercise caution when prescribing mirabegron in patients with risk factors for kidney cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
- Department of Urology, Sorokdo National Hospital, Goheung, Korea.
- Division of Urban Society Research, Seoul Institute, Seoul, Korea.
- Department of Urology, Yongin Severance Hospital, Yonsei University Health System, Yongin, Korea.
ORCID-Profile: Won Sik Ham
Förderung
- National Research Foundation of Korea
Zitieren
APA
Park, J. S., Choi, S. B., Kim, J., Jang, W. S., & Ham, W. S. (2025). Impact of β 3 ‐adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder. BJU International. https://doi.org/10.1111/bju.16771
Vancouver
Park JS, Choi SB, Kim J, Jang WS, Ham WS. Impact of β 3 ‐adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder. BJU International. 2025. doi:10.1111/bju.16771
BibTeX
@article{Park2025,
author = {Park, Jee Soo and Choi, Soo Beom and Kim, Jongchan and Jang, Won Sik and Ham, Won Sik},
title = {Impact of β 3 ‐adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16771}
}
EUVIMED